Prosperitas Financial LLC Acquires 2,650 Shares of AbbVie Inc. $ABBV

Prosperitas Financial LLC raised its stake in shares of AbbVie Inc. (NYSE:ABBV) by 13.5% during the second quarter, Holdings Channel reports. The firm owned 22,314 shares of the company’s stock after buying an additional 2,650 shares during the period. AbbVie comprises 1.8% of Prosperitas Financial LLC’s holdings, making the stock its 19th biggest holding. Prosperitas Financial LLC’s holdings in AbbVie were worth $5,615,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. ACT Advisors LLC. lifted its position in shares of AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after buying an additional 41 shares during the period. Willner & Heller LLC raised its stake in AbbVie by 0.7% during the second quarter. Willner & Heller LLC now owns 5,852 shares of the company’s stock worth $1,472,000 after acquiring an additional 43 shares in the last quarter. B.O.S.S. Retirement Advisors LLC increased its position in shares of AbbVie by 3.1% during the 2nd quarter. B.O.S.S. Retirement Advisors LLC now owns 1,427 shares of the company’s stock worth $359,000 after purchasing an additional 43 shares in the last quarter. Fielder Capital Group LLC raised its stake in shares of AbbVie by 1.7% in the second quarter. Fielder Capital Group LLC now owns 2,532 shares of the company’s stock valued at $637,000 after acquiring an additional 43 shares during the last quarter. Finally, Leslie Global Wealth LLC boosted its holdings in shares of AbbVie by 1.5% in the 2nd quarter. Leslie Global Wealth LLC now owns 2,983 shares of the company’s stock worth $751,000 after acquiring an additional 44 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Qulipta migraine expansion: AbbVie reported positive Phase 3 LUNA results for atogepant (Qulipta) in preventing menstrual migraine. The treatment met its primary and secondary endpoints, potentially opening a new indication and supporting intermittent use rather than continuous daily dosing. This could expand Qulipta’s commercial opportunity and reinforce AbbVie’s position in migraine care. AbbVie’s migraine treatment meets late-stage study goal
• Positive Sentiment: Higher HSBC valuation: HSBC raised its price target for AbbVie to $315 from $300 while maintaining a Buy rating, signaling continued confidence in the company’s growth outlook and product pipeline. HSBC adjusts price target on AbbVie
• Positive Sentiment: Dividend maintained: AbbVie declared a quarterly cash dividend of $1.73 per share, payable Nov. 16 to shareholders of record Oct. 15. The unchanged payout supports the stock’s income appeal and reflects continued shareholder-return capacity. AbbVie declares quarterly dividend
• Neutral Sentiment: Pipeline and portfolio developments: Coverage highlighted the growth of Skyrizi and Rinvoq, the planned $10.9 billion Apogee Therapeutics acquisition, an ADARx collaboration and updated real-world data from an eye-implant study. These initiatives may diversify future growth, but their financial impact remains dependent on execution, approvals and clinical outcomes.
• Negative Sentiment: Regulatory setback: The FDA issued a Complete Response Letter for trenibotE, AbbVie’s fast-acting neurotoxin candidate. The action may delay the product’s launch and add uncertainty around the aesthetics pipeline. FDA issues Complete Response Letter for AbbVie’s trenibotE
• Negative Sentiment: Concentration and valuation concerns: Analysts continue to monitor AbbVie’s reliance on Skyrizi and the long-term effects of Humira’s patent-related decline. With the stock trading at a relatively elevated earnings multiple, execution risks and slower-than-expected diversification could limit further upside.

AbbVie Stock Up 1.6%

AbbVie stock opened at $255.00 on Friday. The business’s 50-day simple moving average is $254.54 and its 200 day simple moving average is $230.76. The stock has a market cap of $450.52 billion, a price-to-earnings ratio of 72.03, a P/E/G ratio of 1.13 and a beta of 0.29. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same period in the previous year, the business posted $2.97 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio is currently 195.48%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Piper Sandler increased their price target on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. Guggenheim raised their target price on AbbVie from $261.00 to $288.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. lifted their price target on AbbVie from $260.00 to $280.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Finally, Evercore set a $235.00 price target on shares of AbbVie in a research note on Friday, May 15th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $276.64.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.